Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
A PET-CT will be performed on patients with myeloma after a standard first-line treatment.
The PET-positive patients will receive 4 cycles of Carfilzomb-Revlimid-Dexamethason (KRd),
before a new PET-CT will be performed.